Market closed
MiMedx Group/MDXG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MiMedx Group
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Ticker
MDXG
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
895
Website
MiMedx Group Metrics
BasicAdvanced
$838M
Market cap
10.73
P/E ratio
$0.53
EPS
1.98
Beta
-
Dividend rate
Price and volume
Market cap
$838M
Beta
1.98
52-week high
$9.27
52-week low
$5.47
Average daily volume
455K
Financial strength
Current ratio
3.849
Quick ratio
3.045
Long term debt to equity
10.86
Total debt to equity
11.455
Interest coverage (TTM)
12.49%
Management effectiveness
Return on assets (TTM)
19.47%
Return on equity (TTM)
70.05%
Valuation
Price to earnings (TTM)
10.728
Price to revenue (TTM)
2.221
Price to book
4.99
Price to tangible book (TTM)
6.14
Price to free cash flow (TTM)
15.707
Growth
Revenue change (TTM)
15.41%
Earnings per share change (TTM)
-413.76%
3-year revenue growth (CAGR)
9.27%
3-year earnings per share growth (CAGR)
-11.42%
What the Analysts think about MiMedx Group
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for MiMedx Group stock.
MiMedx Group Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MiMedx Group Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MiMedx Group News
AllArticlesVideos
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
GlobeNewsWire·2 weeks ago
MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
GlobeNewsWire·3 weeks ago
MIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MiMedx Group stock?
MiMedx Group (MDXG) has a market cap of $838M as of October 26, 2024.
What is the P/E ratio for MiMedx Group stock?
The price to earnings (P/E) ratio for MiMedx Group (MDXG) stock is 10.73 as of October 26, 2024.
Does MiMedx Group stock pay dividends?
No, MiMedx Group (MDXG) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next MiMedx Group dividend payment date?
MiMedx Group (MDXG) stock does not pay dividends to its shareholders.
What is the beta indicator for MiMedx Group?
MiMedx Group (MDXG) has a beta rating of 1.98. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.